

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

2617 USOP

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

10,019,074

INTERNATIONAL APPLICATION NO.
PCT/JP00/04036INTERNATIONAL FILING DATE
June 21, 2000PRIORITY DATE CLAIMED
June 22, 1999

TITLE OF INVENTION

PRODUCTION METHOD OF IMIDAZOLE DERIVATIVES

APPLICANT(S) FOR DO/EO/US

Jun-ichi KAWAKAMI

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☐ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is attached hereto (required only if not communicated by the International Bureau).
 - b. ☒ has been communicated by the International Bureau.
 - c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☒ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☒ is attached hereto.
 - b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are attached hereto (required only if not communicated by the International Bureau).
 - b. ☐ have been communicated by the International Bureau.
 - c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).
9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☒ An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11 to 20 below concern document(s) or information included:

11. ☒ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☒ A FIRST preliminary amendment.
14. ☐ A SECOND or SUBSEQUENT preliminary amendment.
15. ☐ A substitute specification.
16. ☐ A change of power of attorney and/or address letter.
17. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
18. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
19. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
20. ☒ Other items or information:
Copy of first page of published application
Copies of Forms 101, 210, 301, 304, 308, 332 and 409
Itemized Return Postcard

Express Mail Label No. EL 916492355 US

Date of Deposit 12/20/01

21. ☒ The following fees are submitted:**BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):**Neither international preliminary examination fee (37 CFR 1.482)
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO
and International Search Report not prepared by the EPO or JPO. \$1040.00International preliminary examination fee (37 CFR 1.482) not paid to
USPTO but International Search Report prepared by the EPO or JPO \$890.00International preliminary examination fee (37 CFR 1.482) not paid to USPTO
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$740.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$710.00International preliminary examination fee (37 CFR 1.482) paid to USPTO
and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00**ENTER APPROPRIATE BASIC FEE AMOUNT =**Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	42 - 20 =	22	x \$18.00
Independent claims	6 - 3 =	3	x \$84.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$280.00

TOTAL OF ABOVE CALCULATIONS =☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above
are reduced by 1/2. +**SUBTOTAL =**Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30
months from the earliest claimed priority date (37 CFR 1.492(f)).**TOTAL NATIONAL FEE =**Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +**TOTAL FEES ENCLOSED =**

Amount to be refunded:	\$
charged:	\$

- a. ☐ A check in the amount of \$ _____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 500799 in the amount of \$ 1538.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. 500799. A duplicate copy of this sheet is enclosed.
- d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card
information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR
1.137 (a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Mark Chao, PhD, JD
Takeda Pharmaceuticals North America, Inc.
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA
(847)383-3372 fax (847)383-348

SIGNATURE

Mark Chao, PhD, JD

NAME

37,293

REGISTRATION NUMBER

For Customer No. 23,115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.:	tba	Art Unit:	tba
Filed:	tba	Examiner:	tba
1 st Inventor:	J. KAWAKAMI	Allowed:	
For:	Production Method of Imidazole Derivatives	Batch:	
Atty. Dkt. No.	2617 USOP	Paper No.:	

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10**USPS EXPRESS MAIL LABEL. No. EL 916492355 US****DATE IN: December 20, 2001****12-20-2001****Itemized Papers/Items:**

U.S. Patent & TMO/TM Mail Rcpt Dt. #70


1. This Postcard and Certificate of Express Mailing (2 pages)
2. Transmittal Letter for Filing under 35 USC 371 (2 pages X 2)
3. Preliminary Amendment (28 pages)
4. Copy of Request form of the International Application PCT/JP00/04036, (Form PCT/RO/101)(4 pages)
5. English Translation of the International Application as filed in Japanese [This includes Specification total 41 pages, including Claims (pages 34-40), Abstract (1 page)]
6. Information Disclosure Statement (1 page) with Form PTO-1449 (1 page), and copies of references (5)
7. Copy of Forms PCT/IB/301, 304, 308 and 332 (5 pages)
8. Copy of the front page of the International Application as published (WO 00/78727) (1 page)
9. Copy of International Preliminary Examination Report (4 pages)
10. Copy of International Search Report (2 pages)

The undersigned hereby certifies that the above itemized papers are together being deposited with the Express Mail Post Office to Addressee service of the United States Postal Service (USPS) in an envelope with sufficient postage, having the USPS Express Mail Label No. shown above, and addressed to:

BOX PCT
Commissioner for Patents
Washington, D.C. 20231.

on this date, 12/20/01

Dated: 12/20/01


Gail L. Winokur